Introduction {#s1}
============

Laryngeal squamous cell carcinoma (LSCC) is one of the common malignant tumors of the head and neck. Recent data from global epidemiology of head and neck cancers show that more than 245,000 new cases of laryngeal cancer will be expected by 2030 ([@B9]). Although great significant progress has made in the diagnosis, its early diagnosis rate of LSCC still remains to be raised. Microbubble-based ultrasound molecular imaging (USMI) shows significant potential in the early diagnosis of tumors. Ultrasound contrast agents (UCAs) such as microbubbles (MBs) can emit significantly stronger acoustic signals under an appropriate sonic energy excitation, making them several thousand times more reflective than normal body tissues. Through designing ultrasonic contrast agents with specific molecular markers, USMI probes can be obtained and used to visualize molecular and genetic alterations of diseased cells, and to monitor the genesis and development of certain diseases. Previously, researchers have demonstrated that the MBs combined with antibodies or peptides, which can bind to vascular endothelial growth factor (VEGR) or αvβ3 integrin, and enhanced the contrast ultrasonography quality in LSCC *via* USMI ([@B17]; [@B12]). However, in malignant LSCC tumors, the expression of EGFR or αvβ3 integrin was commonly not at a high level ([@B14]; [@B8]).

Matrix metalloproteinase-1 (MMP-1), a member of the family of MMPs, plays crucial roles in vascular formation and remodeling *via* degrading vascular membrana basilaris and extracellular matrix (ECM) proteins ([@B20]). In addition, several studies have confirmed that the MMP-1 is specially associated with LSCC growth, local invasion, and metastasis ([@B24]). [@B25] had claimed that the angiogenesis of LSCC was not only a unique means to nourish tumor tissues. Specially, it generated "micro-vascular" channels without the composition of endothelial cells at the early stage. This event was known as vascular mimicry (VM) in which endothelial-like cells are transdifferentiated by their own stem cells. More importantly, both angiogenesis and VM as a part of tumor microenvironment are coordinately providing tumor initiation and progression, and the latter one even seriously contributed to the invasion of LSCC ([@B25]; [@B2]). In view of above-mentioned reasons, we believed that the biomarker of MMP-1 would provide a potential evaluation of its progress in LSCC biology, thus allowing for the design of new diagnostics and therapeutics for early cancer diagnosis and treatment.

To date, the positive rate of conventional medical imaging examination, such as computed tomography (CT) and magnetic resonance imaging (MRI), in detecting LSCC is still low in detection of LSCC ([@B4]; [@B28]; [@B16]; [@B21]). USMI is a multifunctional and famous medical imaging tool for the detection and visualization of cancer-related biomarkers in early disease diagnosis ([@B18]; [@B29]; [@B7]; [@B27]). In the past decades, MBs with different types of shells composed of phospholipids or polymers and gas cores (perfluorocarbon, nitrogen, sulfur hexafluoride, or air) had been applied in USMI and performed good contrast enhancement ([@B13]; [@B1]). Some special biomarkers of ligands such as integrin and Vascular cell adhesion molecule-1 (VCAM-1) or EGFR can be tightly bound on the surface of MBs for a better specificity diagnosis ([@B6]). Recently, it has been successfully applied to various diseases such as vascular plaque and tissue inflammation, but its potential use in the diagnosis of LSCC has not been reported. In our study, we preliminarily developed the MB~MMP-1~ and dynamically evaluated the expression of MMP-1 separately at Day 7, Day 12, and Day 17 of LSCC progression *in vivo* by USMI.

Materials and Methods {#s2}
=====================

Preparation of MB~MMP-1~ {#s2_1}
------------------------

MB~MMP-1~ and control MB~IgG~ were prepared according to a previous report ([@B23]). In brief, DSPC: DSPE-PEG2000:DSPE-PEG2000-biotin (Avanti Polar Lipids, Alabaster, AL, USA) (molar ratios = 9:0.5:0.5) was blended in chloroform, and the solvent was removed under nitrogen flow at room temperature, followed by vacuum treatment over 2 h. The dried blends were hydrated at 60°C with phosphate-buffered saline (PBS) and sub-packaged into vials (1 mL each vial). After that, perfluoropropane (C~3~F~8~; Flura, Newport, TN, USA) was added, and the admixture was mechanically vibrated for 45 s. After that, MB~MMP-1~ contrast group was prepared by incubating these biotinylated MBs with excess avidin, followed by adding a given proportion (50 μg × 10^8^ MBs) of biotinylated anti-mouse MMP-1 monoclonal antibody (ဂNovus Biologicals, Colorado, USA). Incubation at room temperature for 15--30 min and washing three to four times by centrifugation (400*g*) were necessary for avidin or antibody linkage. The biotinylated IgG antibody (Novus Biologicals, Colorado, USA) was used instead of MMP-1 to connect with biotinylated MBs in the same way to obtain MB~IgG~ in the control group.

Characterization of MB~MMP-1~ {#s2_2}
-----------------------------

The surface morphology of MB~MMP-1~ was investigated using a microscope (Leica DMI3000 B). Fluorescent microscopic examination was performed to verify the anti-mouse MMP-1 monoclonal primary antibody conjugation efficiency of MB~MMP-1~ according to fluorescent intensity of fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse second antibody (St. Louis, MO, USA) under a fluorescent microscope (Olympus, Tokyo, Japan). MB~MMP-1~ average size, distribution, and differential intensity were evaluated three times for each sample using a diameter limit of 0.5 μm (AccuSizer 780; Particle Sizing Systems, Santa Barbara, CA, USA).

Cell Culture {#s2_3}
------------

Human epidermoid laryngeal cancer cells (Procell Life, Wuhan, China) (HEp-2) were cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% l-glutamine, and 1% penicillin--streptomycin. The cell cultures were maintained in a humidified atmosphere of 5% CO~2~ at 37°C with the medium changed every other day.

Tumor Model {#s2_4}
-----------

All animal studies were approved by the Institute's Animal Care and Use Committee of Shenzhen Second People's Hospital, Guangzhou University School of Medicine, China. The methods were carried out in accordance with the approved guidelines. Nude male Balb/c mice (6- to 8-week-old, body weight 20 ± 1.5 g) were supplied by Beijing Vital River Laboratory Animal Technology Co. Ltd. All mice were housed on a 12:12 light:dark cycle with free access to food and water. HEp-2 cells (1 × 10^6^/each mouse) dissolved in 100 μL of PBS were injected into the left oxter of nude male Balb/c mice. Tumor-bearing mice were used for USMI when they had developed at Day 7, Day 12, and Day 17 after inoculation.

*In Vitro* Imaging Performance of MB~MMP-1~ {#s2_5}
-------------------------------------------

MB~MMP-1~ with concentrations of 1 × 10^5^, 1 × 10^6^, and 1 × 10^7^ MBs/mL was placed in agar gel holes. The US imaging performance of MBs was detected from the side of the agar gel with VisualSonics Vevo2100 (VisualSonics, Inc., Toronto, Canada) to determine the intensity of the ultrasound signal of the MBs with concentrations of 1 × 10^5^, 1 × 10^6^, and 1 × 10^7^ MBs/mL.

Binding Specificity of MB~MMP-1~ to Human Epidermoid Laryngeal Cancer Cells {#s2_6}
---------------------------------------------------------------------------

In a 6-well plate (1 × 10^5^ cells per well), 1 × 10^5^ HEp-2 cells were cultured overnight. The next day, the culture medium was discarded, and the cells were washed three times with PBS, and then 1 × 10^8^ MBs/mL of MB~MMP-1~ or MB~IgG~ was added to the cells and incubated to the plate for 5--6 min. After being washed three to five times with PBS, the binding efficiency of MB~MMP-1~ and control MB~IgG~ to cells was examined under an inverted microscope (Olympus, Tokyo, Japan). At the same time, the competitive binding inhibition experimental group (pre-blocking MMP-1 receptors by adding an excess of free MMP-1 monoclonal antibody) was also set up to study the binding specificity of MB~MMP-1~ to HEp-2.

*In Vivo* Ultrasound Molecular Imaging {#s2_7}
--------------------------------------

USMI was conducted as described previously ([@B23]). Briefly, the mice were kept anesthetized by continuous inhalation of 2% isoflurane in oxygen at 2 L/min on a heated stage during scanning. US imaging was performed using a dedicated small-animal high-resolution USMI system (Vevo2100, VisualSonics) equipped with an 18-MHz high-frequency nonlinear transducer. All imaging parameters (grain, 30 dB; focal depth, 2--4 mm; transmit power, 10%; MI, 0.1) were kept constant during all imaging sessions. MB~MMP-1~ or MB~IgG~ (5 × 10^8^ MBs in 200 μL of PBS) was administered *via* the tail vein of the mice in random order to minimize bias, and injections were separated by at least 30 min to allow clearance of MBs from the blood circulation. To distinguish the acoustic signal from MBs that had adhered to MMP-1 receptors from the signal from freely circulating MBs, a destruction/replenishment approach was used in this study. In brief, after injection of MBs and waiting for 7 min, approximately 200 ultrasonographic frames of the tumor were acquired at a temporal resolution of 12 s. Then a high-power ultrasound destruction sequence was applied for 1 s to destroy the MBs. After the destruction pulse, another set of movie (≈200 frames) was acquired. Movie processing and quantification were performed using Vevo2100 built-in software of CQ and relying on two sets of movie: a pre-destruction set and a post-destruction (background) data set. The post-destruction movie signals were subtracted from the pre-destruction signals. The difference in movie signal intensity between pre-destruction and post-destruction ultrasonographic frames was calculated and expressed as movie intensity amplitude.

Imaging Data Analysis {#s2_8}
---------------------

The imaging data sets of all mice were analyzed by Vevo2100 built-in software CQ. Regions of interest were drawn covering the entire area of the tumor. The movie signal intensity from attached MBs was assessed by calculating an average for pre-destruction and post-destruction imaging signals and subtracting the average post-destruction signal from the average pre-destruction signal. The subtracted signal, so-called differential targeted enhancement (dTE), was colored red and then displayed as a colored overlay on the contrast-mode images.

Immunofluorescence {#s2_9}
------------------

Tumor-bearing mice were euthanized after USMI, and the subcutaneous tumors were excised, embedded in optimal cutting temperature compound, and frozen in dry ice. Frozen blocks were sectioned at 5 μm (CM1950, Leica, Heidelberg, Germany) and mounted on glass slides for immunofluorescence staining. A double-staining procedure was employed to visualize MMP-1 expression on tumor cells. The following method was used for mouse MMP-1 staining. First, paraffin sections were successively dewaxed with xylene I for 15 min and xylene II for 15 min; hydrated with absolute ethanol I for 5 min, absolute ethanol II for 5 min, 85% ethanol for 5 min, and 75% ethanol for 5 min; and afterwards washed with distilled water. Second, these were subsequently blocked with 5% goat serum for 30 min at room temperature. And then the slides were co-incubated with rabbit anti-mouse MMP-1 primary antibody with dilution 1:1,500 ratio (Google Biotechnology Co., Ltd, Wuhan, China) overnight at 4°C and visualized by using Cy3-conjugated goat anti-rabbit second antibody (Servicebio, Wuhan, China) in a 1:300 ratio (Google Biotechnology Co., Ltd, Wuhan, China). Next, the slides were placed in PBS (pH 7.4) on as decolorization shaking table for 5 min. After the drying process, dihydrochloride (DAPI) dye was added to the slides, and samples were protected from light and incubated for 10 min. Finally, fluorescent images were acquired at ×400 magnifications with a laser scanning confocal microscope (TCS SP5, Leica, Germany). And then the correlation analysis between the signal intensity of USMI and mean optical density (/pixel) of MMP-1 expression was performed separately at Day 7, Day 12, and Day 17.

Statistical Analysis {#s2_10}
--------------------

Quantitative data were expressed as the means and standard deviation (mean ± SD). Data from two independent samples were analyzed with Student's *t* test. Analysis of variance (ANOVA) was used to determine the significance of differences in multiple comparisons. A *P* value of less than 0.05 was considered statistically significant. Statistical analyses were performed using Statistical Product and Service Solutions (SPSS) software version 13.0 (SPSS Inc, Chicago, IL, USA).

Results {#s3}
=======

Characterization of MB~MMP-1~ {#s3_1}
-----------------------------

[**Figure 1**](#f1){ref-type="fig"} shows a schematic illustration of MB~MMP-1~. Microscopic image analysis at high magnification revealed that the resulting MB~MMP-1~ has regular spherical morphology, transparent center, and good dispersion with no adherence to each other ([**Figure 2A**](#f2){ref-type="fig"}). The FITC-conjugated MB~MMP-1~ shows bright green fluorescence under fluorescence microscope ([**Figure 2B**](#f2){ref-type="fig"}), indicating the successful conjugation of anti-MMP-1 antibodies onto the surface of MBs. Mean size distributions of the MB~MMP-1~ are shown in [**Figure 2C**](#f2){ref-type="fig"} by AccuSizer 780, revealing that the mean diameter of the MB~MMP-1~ was centered at 1.11 ± 0.10 µm.

![Schematic illustration of MB~MMP-1~. DSPC = distearoylphosphatidylcholine; DSPE = distearoylphosphatidylethanolamine; PEG2000 = polyethylene glycol 2000.](fphar-10-00655-g001){#f1}

![In vitro US imaging performance. **(A)** 1×105 MBs/mL. **(B)** 1×106 MBs/mL. **(C)** 1×107 MBs/mL. **(D)** Quantitative analysis of US signal intensity of MBMMP-1 with three different concentrations.](fphar-10-00655-g002){#f2}

*In Vitro* Imaging Performance of MB~MMP-1~ {#s3_2}
-------------------------------------------

To confirm the imaging performance of MB~MMP-1~ as a contrast agent for USMI, three different concentrations of MB~MMP-1~ were assessed *in vitro via* contrast imaging mode ([**Figure 3A, B, C**](#f3){ref-type="fig"}). We found the three samples' echoes are relatively well distributed. In addition, with the increase of the concentration of MB~MMP-1~, the signal intensity of contrast imaging increases. In particular, we found that the best performance of contrast imaging was at 1 × 10^7^ MBs/mL. Then, we quantified the average signal intensity of different concentrations of MB~MMP-1~, revealing 4.11 ± 1.37, 24.03 ± 2.06, and 90.72 ± 4.92 a.u. at 1 × 10^5^, 1 × 10^6^, and 1 × 10^7^ MBs/mL, respectively ([**Figure 3D**](#f3){ref-type="fig"}).

![Characterization of MB~MMP-1~. **(A)** Bright-filed photograph of MB~MMP-1~. **(B)** Fluorescent micrograph of FITC-labeled MB~MMP-1~. **(C)** Average size and distribution of the MB~MMP-1~ (scale bar = 10 µm).](fphar-10-00655-g003){#f3}

Binding Specificity of MB~MMP-1~ to Human Epidermoid Laryngeal Cancer Cells {#s3_3}
---------------------------------------------------------------------------

To ensure the binding specificity of the MB~MMP-1~, we further conducted the binding specificity of MB~MMP-1~ or MB~IgG~ with the HEp-2 by comparing with the group that was pre-incubated with free anti-MMP-1 antibodies for 5--6 min. In bright field, our results ([**Figure 4A**](#f4){ref-type="fig"}) showed that the control MB~IgG~ only had a small number of non-targeted binding specificity on the HEp-2 surface with 12.38 ± 3.26 MBs/per field, while the MB~MMP-1~ could specifically bind to the HEp-2 with 298.42 ± 16.57 MBs/per field ([**Figure 4B**](#f4){ref-type="fig"}) (298.42 ± 16.57 versus 12.38 ± 3.26 MBs/per field, *P* \< 0.01). And as for the pre-blocking group by an excess of free anti-MMP-1 monoclonal antibody, it was found that the number of MB~MMP-1~ attached to HEp-2 was significantly decreased with 37.3 ± 6.94 MBs/per field ([**Figure 4C**](#f4){ref-type="fig"}) (298.42 ± 16.57 versus 37.3 ± 6.94 MBs/per field, *P* \< 0.01). Quantitative analysis indicated that the binding specificity of MB~MMP-1~ was significantly about 20 times higher than that of control MB~IgG~ (298.42 ± 16.57 versus 12.38 ± 3.26, \*\**P* \< 0.01) ([**Figure 4D**](#f4){ref-type="fig"}).

![*In vitro* binding specificity experiment of MB~MMP-1~ to human epidermoid laryngeal cancer cells (HEp-2). **(A)** White light micrograph after incubating control group MB~IgG~ with HEp-2 cells. **(B)** White light micrograph after incubating MB~MMP-1~ with HEp-2 cells. **(C)** White light micrograph after incubating pre-blocked with free anti- matrix metalloproteinase-1 (MMP-1) antibody. **(D)** Quantitative analysis of the number of MB~MMP-1~ and control group MB~IgG~ that adhered onto HEp-2 from five random view fields (\*\**P* \< 0.01, *n* = 5). Scale bar = 10 µm.](fphar-10-00655-g004){#f4}

USMI *In Vivo* {#s3_4}
--------------

MB~MMP-1~ and MB~IgG~ were further evaluated in tumor-bearing mice at Day 7, Day 12, and Day 17 by USMI. The injections of MB~MMP-1~ or MB~IgG~ were separated by at least 30 min. From [**Figure 5A**](#f5){ref-type="fig"}, we could clearly observe that the MB~MMP-1~ of color red had more retention rate in tumors and significantly enhanced the US imaging signal intensity, while the control MB~IgG~ showed a significantly lower enhancement than did MB~MMP-1~. In addition, with the growth of LSCC, the dTE signal intensity was much higher in MB~MMP-1~. From [**Figure 5B**](#f5){ref-type="fig"}, we plotted the US dTE signal intensity from the LSCC versus growth time of the Day 7, Day 12, and Day 17. There were 20-, 10- and 8-folds higher dTE signal intensity from MB~MMP-1~ than control MB~IgG~. Then we quantify the dTE signal intensity with Vevo2100 inner software CQ. Quantification revealed 41.21 ± 15.00 a.u. for MB~MMP-1~ versus 2.25 ± 0. 6 a.u. for MB~IgG~ at Day 7 (\**P* \< 0.05), 124.64 ± 5.19 a.u. MB~MMP-1~ versus 11.13 ± 1.13 a.u. MB~IgG~ at Day 12 (\**P* \< 0.05), and 332.01 ± 64.88 a.u. MB~MMP-1~ versus 42.99 ± 11. 9 a.u. MB~IgG~ at Day 17 (\*\**P* \< 0.01).

![Ultrasound molecular imaging (USMI) *in vivo*. **(A)** Color-coded differential targeted enhancement (dTE) signal sonograms separately at Day 7, Day 12, and Day 17. **(B)** Quantitative analysis of dTE for the MB~MMP-1~ and control group MB~IgG~ (\**P* \< 0.05, \*\**P* \< 0.01).](fphar-10-00655-g005){#f5}

Tumor Immunofluorescence Staining {#s3_5}
---------------------------------

To confirm the results of USMI using the MB~MMP-1~, the tumor slices at Day 7, Day 12, and Day 17 were executed and subsequently analyzed for MMP-1 expression by immunofluorescence. Immunofluorescence results are shown in [**Figure 6**](#f6){ref-type="fig"}; we could clearly see that the MMP-1 (red) was highly expressed in LSCC, confirming the presence of mouse MMP-1 on plasma membrane within LSCC in our study. In addition, we did the correlation analysis between the dTE signal intensity of USMI and mean optical density (/pixel) of MMP-1 expression in [**Figure 7**](#f7){ref-type="fig"}; it was obvious that the dTE signal intensity of USMI was linearly enhanced as the mean optical density under the growth of the tumor. On the whole, the results of immunofluorescent evaluation at Day 7, Day 12, and Day 17 are relevant to the dTE signal intensity acquired with the MB~MMP-1~ by USMI.

![Immunofluorescence staining of HEp-2 tumors for MMP-1 receptor. Immunofluorescence images of cell nucleus blue (first column), mouse MMP-1 red (second column), and merged (third column) MMP-1 and cell nucleus-stained image (the overlap of blue and red fluorescence confirms the co-localization of MMP-1) proved the expression of MMP-1 on plasma membrane in HEp-2 cells. MMP-1 was visualized with Cy3 dye (red). Cell nuclei were stained with DAPI (St. Louis, MO, USA) (blue). Scale bar = 200 µm.](fphar-10-00655-g006){#f6}

![dTE signal intensity of USMI and mean optical intensity (/pixel) images of tumor immunofluorescence staining separately at Day 7, Day 12, and Day 17.](fphar-10-00655-g007){#f7}

Discussion and Conclusion {#s4}
=========================

Previous research had developed and tested arginine-glycine-aspartate (RGD)-MBs using αvβ3 integrin for a biomarker of the neovasculature in HEp-2 mouse tumor model ([@B12]). It had been proven that αvβ3 integrin-targeted RGD-MBs could effectively assess the expression of neovasculature and enhance the contrast imaging signal. However, the specificity of αvβ3-targeted MBs for LSCC detection was still not high enough because of its universality of expression in various types of malignant tumors ([@B22]; [@B3]; [@B10]). Despite the growing number of published studies on USMI, a main obstacle for a clinical early diagnosis still exists.

In 1999, Maniotis and colleagues found the existence of VM in human melanoma cells ([@B15]). Subsequently, more and more studies had confirmed that VM is the new generation of tumor microcirculation without the participation of endothelial cells ([@B15]; [@B26]). And in tumor environment, it also was of importance to LSCC aggression and facilitates distant metastasis ([@B15]; [@B19]). On the basis of these events, we assume that the lipid-shelled MBs loaded with mouse anti-MMP-1 monoclonal antibodies could tightly gather around VM to evaluate the expression of MMP-1 in LSCC.

In our current study, a novel MB~MMP-1~ USMI agent with C~3~F~8~-filled lipid-shelled MBs were prepared to dynamically evaluate the expression of MMP-1 in LSCC separately at Day 7, Day 12, and Day 17. First, we found that the MB~MMP-1~ had the ideal particle size range and that 1 × 10^8^ MBs/mL concentration enhanced the US imaging signal *in vitro*. Then, we further confirmed the specific binding ability of MB~MMP-1~ to HEp-2. It revealed that MB~MMP-1~ not only exhibited significantly greater adhesion to HEp-2 than did control MB~IgG~ but also significantly provided a prospecting result for the next animal experiment. *In vivo*, we clearly found that the signal intensity of dTE of MB~MMP-1~ group had significantly higher retention than did control MB~IgG~ between each group. In addition, it is also noticeable that the signal intensity of dTE showed an upward trend with the time increasing of tumor. This result could be because a much more universal VM was newborn in the later period of LSCC than in the early period ([@B26]). A further study also confirmed that more and more newborn VM were increasing the participates in cancer progression and metastasis to supply tumor with sufficient nutrition ([@B11]). As expected, these *in vivo* dynamical evaluation results are further confirmed by immunofluorescence. From [**Figure 6**](#f6){ref-type="fig"}, the red-stained MMP-1 receptors were much more expressed with the growth of tumors. This immunofluorescence analysis was well correlated with the results from signal intensity of dTE by USMI *in vivo* ([**Figure 7**](#f7){ref-type="fig"}).

The following limitations of the study need to be solved. First, the size of MBs we chose is of microsize level, which can only indirectly draw support from no endothelial cells' VM by USMI. Second, although there was a strong significance in evaluating the expression of MMP-1 in LSCC, contrast agents adhering to more than one molecular biomarker may be advantageous over single-targeted contrast agents ([@B5]) by increasing the number of MBs attached at sites of tumor neovascular and tumor tissue.

In conclusion, a novel MB~MMP-1~ US contrast agent will lay the foundation for the application of target biomarker of LSCC for USMI and will be a promising method to improve the early diagnosis.
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